Core Viewpoint - Parks! America, Inc. reported its financial results for the second fiscal quarter ended March 30, 2025, highlighting both revenue and loss figures across its parks [1][2]. Financial Performance - Total revenue for the 13 weeks ended March 30, 2025, was $2,002,021, compared to $1,958,200 for the same period in 2024, reflecting an increase of approximately 2.2% [3]. - For the 26 weeks ended March 30, 2025, total revenue was $3,772,479, down from $3,855,825 in 2024, indicating a decrease of about 2.2% [3]. - Georgia Park generated revenue of $1,046,387 for the 13 weeks ended March 30, 2025, slightly down from $1,048,944 in 2024 [3]. - Missouri Park's revenue decreased from $400,733 in 2024 to $374,328 in 2025 for the 13 weeks [3]. - Texas Park saw an increase in revenue from $508,523 in 2024 to $581,306 in 2025 for the 13 weeks [3]. Loss Before Income Taxes - The consolidated loss before income taxes for the 13 weeks ended March 30, 2025, was $(328,762), compared to $(1,344,724) in 2024, showing a significant improvement [3]. - Georgia Park reported a loss before income taxes of $148,542 for the 13 weeks, down from $185,645 in 2024 [3]. - Missouri Park's loss before income taxes improved from $(50,940) in 2024 to $(6,806) in 2025 for the 13 weeks [3]. - Texas Park's loss before income taxes increased from $31,076 in 2024 to $67,073 in 2025 for the 13 weeks [3]. Capital Expenditures - Consolidated capital expenditures for the 13 weeks ended March 30, 2025, were $484,909, compared to $254,706 in 2024, indicating a significant increase [3]. - Georgia Park's capital expenditures rose from $182,515 in 2024 to $443,018 in 2025 for the 13 weeks [3]. - Missouri Park's capital expenditures decreased from $60,271 in 2024 to $25,623 in 2025 for the 13 weeks [3]. - Texas Park's capital expenditures increased from $11,920 in 2024 to $16,268 in 2025 for the 13 weeks [3]. Assets Overview - Total assets as of March 30, 2025, were $18,270,953, down from $19,194,071 as of September 29, 2024 [4]. - Total cash and short-term investments decreased from $3,324,368 in September 2024 to $1,973,551 in March 2025 [4]. - Georgia Park's total assets decreased from $7,520,918 to $7,238,010 [4]. - Missouri Park's total assets decreased from $3,399,324 to $3,059,835 [4]. - Texas Park's total assets remained relatively stable, decreasing slightly from $7,812,661 to $7,800,448 [4].

Core Viewpoint - Matador Technologies Inc. is conducting a non-brokered private placement offering to raise up to C$3,000,000 by issuing units priced at $0.55 each, aimed at enhancing its Bitcoin-focused operations and other business initiatives [1][5]. Group 1: Offering Details - The offering consists of up to 5,454,546 units, each unit comprising one common share and one-half of a common share purchase warrant [1][2]. - Each warrant allows the holder to purchase an additional common share at a price of $0.75 for twelve months from issuance [2]. - An acceleration clause is included, allowing the company to shorten the warrant expiry if the share price exceeds $1.05 for five consecutive trading days [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated approximately one-third each to the purchase of Bitcoin, advancing gold acquisition initiatives, and general corporate purposes [5]. Group 3: Company Overview - Matador Technologies Inc. is a publicly traded company focused on the Bitcoin ecosystem, holding Bitcoin as its primary treasury asset and developing products to enhance the Bitcoin network [6]. - The company's flagship product, the Digital Gold Platform, allows users to trade 1-gram gold units inscribed as Bitcoin Ordinals, integrating traditional value with decentralized technology [7].

Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing ALS patients in late 2025 BOTHELL, Wash., May 09, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, ...

JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. “During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. (“OPKO”). EB613 ...

- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months- Initiated utilization of share repurchase program- Cash and restricted cash balance of approximately $27 million at end of Q1 2025, reinforcing financial stability TARPON SPRINGS, Fla., May 9, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing sten ...

LONDON, May 09, 2025 (GLOBE NEWSWIRE) -- Navigator Holdings Ltd. (described herein as “Navigator Gas” or the “Company”) (NYSE: NVGS), the owner and operator of the world’s largest fleet of handysize liquefied gas carriers, announces the following change to its board of directors (the “Board”) with effect from June 16, 2025: Yngvil Åsheim, who joined the Company’s Board in June 2023, as a designee of BW Group Limited, and who served on and contributed significantly to the Company’s Compensation and ESG Commi ...

SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. Business Highlights Surrozen has pivoted its focus to its ophthalmology pipeline, leveraging its Wnt biolog ...

VANCOUVER, British Columbia, May 09, 2025 (GLOBE NEWSWIRE) -- Fancamp Exploration Ltd. (“Fancamp” or the “Corporation”) (TSX Venture Exchange: FNC) announces that it has entered into a settlement agreement (the “Settlement Agreement”) with a former director of the Corporation (the “Former Director”) to resolve the Litigation Proceedings (as defined herein) between the parties (the “Settlement”). The Litigation Proceedings involved a statement of claim filed by the Former Director and his controlled entity ( ...

MINNEAPOLIS, May 09, 2025 (GLOBE NEWSWIRE) -- Nortech Systems Incorporated (Nasdaq: NSYS) (the “Company”), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical imaging, medical device, aerospace & defense and industrial markets, will hold a live conference call and webcast at 3:30 p.m. Central Time on Wednesday May 14, 2025, to discuss the Company's first quarter 2025 financial results. The call will be hosted by Jay D. M ...

WINTER PARK, Fla. and SALT LAKE CITYWINTER PARK, Fla., May 09, 2025 (GLOBE NEWSWIRE) -- Integrated Rail & Resources Acquisition Corp. (OTC: IRRX) (“IRRX”) and Shell Trading (US) Company (“Shell”) have entered into a 7-year supply and offtake agreement under which STUSCO will supply crude oil feedstock to, and purchase certain refined products from, a facility to be acquired by IRRX. Once completed, the facility will initially have the capacity to process 15,000 barrels of crude oil per day, producing LPG, N ...